U.S. Markets open in 1 hr 20 mins
  • S&P Futures

    4,276.25
    -41.50 (-0.96%)
     
  • Dow Futures

    33,693.00
    -350.00 (-1.03%)
     
  • Nasdaq Futures

    13,869.00
    -117.75 (-0.84%)
     
  • Russell 2000 Futures

    1,901.10
    -27.20 (-1.41%)
     
  • Crude Oil

    87.34
    +0.73 (+0.84%)
     
  • Gold

    1,784.80
    -8.30 (-0.46%)
     
  • Silver

    22.49
    -0.19 (-0.84%)
     
  • EUR/USD

    1.1138
    -0.0009 (-0.0780%)
     
  • 10-Yr Bond

    1.8070
    0.0000 (0.00%)
     
  • Vix

    32.65
    +0.69 (+2.16%)
     
  • GBP/USD

    1.3384
    +0.0002 (+0.0174%)
     
  • USD/JPY

    115.5750
    +0.2730 (+0.2368%)
     
  • BTC-USD

    36,341.49
    -430.26 (-1.17%)
     
  • CMC Crypto 200

    823.39
    +3.89 (+0.47%)
     
  • FTSE 100

    7,420.64
    -133.67 (-1.77%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     
  • Oops!
    Something went wrong.
    Please try again later.

UPDATE 1-J&J raises 2021 profit view, keeps vaccine sales outlook unchanged

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • JNJ

(Adds details on forecast, background) 

  Oct 19 (Reuters) - Johnson & Johnson on Tuesday raised its adjusted profit forecast for 2021, even as it stuck to its outlook of $2.5 billion in sales from its COVID-19 vaccine this year. 

  The company raised its annual adjusted earnings forecast to between $9.77 per share and $9.82 per share, from its prior estimates of $9.60 to $9.70 per share. 

  The drugmaker had faced major problems with the production of its COVID-19 vaccine earlier this year, when quality problems at a Baltimore manufacturing facility wasted millions of doses, leading to delays. 

  J&J in July said it expects to produce 500 million to 600 million doses of its one-shot vaccine this year, down from its goal to make a billion shots. 

  The U.S. Food and Drug Administration's independent advisers last week recommended authorizing a second dose of J&J's vaccine for all recipients of the one-dose inoculation. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)